NR3C2 and type 2 diabetes mellitus: In addition, finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced the risks of CKD progression and cardiovascular events in patients with CKD and type 2 diabetes compared with placebo in the FIDELIO-DKD trial; meanwhile, the overall rates of adverse events were similar in both groups [51].